Hepatitis C virus infection. New England Journal of Medicine, 2001. 345(1): p. 41–52.
National Hepatitis C Prevention Strategy: A Comprehensive Strategy for the Prevention and Control of Hepatitis C Virus Infection and its Consequences. 2001, Centers for Disease Control: Atlanta, GA.
Hepatitis C: 170 million infected worldwide and still no vaccine. 1998, World Health Organization: Geneva.
et al., Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis, 2000. 30 Suppl 1: p. S77–84.
Prevalence and characteristics of HCV co-infection in a community based HIV clinical trials group. in 1st IAS Conference on HIV Pathogenesis and Treatment. 2001. Buenos Aires, Argentina. ,
et al., Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis, 2002. 34(6): p. 831–7.
et al., Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med, 2002. 17(2): p. 134–43.
et al., Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection. Am J Public Health, 2002. 92(4): p. 670–6.
et al., Viral Hepatitis and Other Infectious Diseases in a Homeless Population. J Clin Gastroenterol, 2002. 34(4): p. 476–480.
et al., Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health, 2001. 91(1): p. 46–7.
et al., Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis, 2001. 20(4): p. 15–25.
et al., Differences among patients infected with HIV and hepatitis C (HCV) versus those infected with HCV alone in an urban hospital clinic. in 39th Annual Meeting of the Infectious Diseases Society of America. 2001. San Francisco, CA. ,
et al., Costs of hepatitis C. Arch Intern Med, 2001. 161(18): p. 2231–7.
et al., Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med, 2002. 162: p. 2545–2556.
et al., Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Jama, 2003. 290(2): p. 228–37.
et al., Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. Aids, 2001. 15(15): p. 2011–6.
Comparison of the severity of liver disease in HCV-non-HIV-infected patients and HCV-HIV co-infected patients prior to HCV-treatment in an urban area. in Digestive Disease Week. 2001, Atlanta, GA.
et al., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 2000. 356(9244): p. 1800–5.
et al., Trends in Causes of Death in Persons with AIDS in the Era of Highly Active Antiretroviral Therapy, San Francisco: 1994–1998. Journal of Infectious Diseases, 2002 (in press).,
et al., Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis, 2001. 33(2): p. 240–7.
et al., Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis, 2001. 32(3): p. 492–7.
et al., Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr, 2002. 29(1): p. 41–8.
et al., Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology, 2002. 35(1): p. 182–9.
et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001. 358(9286): p. 958–65.
A Randomized, Controlled Trial of Pegylated Interferon alfa-2a with Ribavirin vs Interferon alfa-2a with Ribavirin for the Treatment of Chronic HCV in HIV Co-Infection: ACTG A5071. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA. ,
Factors associated with the health care utilization of homeless persons. Jama, 2001. 285(2): p. 200–6.
, , and ,
et al., Mortality in a cohort of homeless adults in Philadelphia. N Engl J Med, 1994. 331(5): p. 304–9.
Health promotion in the city: a review of current practice and future prospects in the United States. Annu Rev Public Health, 2000. 21: p. 473–503.
et al., Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med, 1994. 330(11): p. 763–8.
et al., Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med, 1993. 118(8): p. 593–601.
et al., Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health, 1986. 76(12): p. 1446–8.
Ethnicity as a risk factor for inadequate emergency department analgesia. Jama, 1993. 269(12): p. 1537–9.
, , and ,
et al., Prevalence, detection, and treatment of alcoholism in hospitalized patients. Jama, 1989. 261(3): p. 403–7.
et al., Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. Jama, 1992. 268(11): p. 1434–40.
et al., Treatment modality and quality differences for black and white breast- cancer patients treated in community hospitals. Med Care, 1989. 27(10): p. 942–58.
et al., HIV seroprevalence and risk factors in a representative sample of homeless and marginally housed adults in San Francisco. AJPH, 2003. in press. ,
The prevalence of specific psychiatric disorders among homeless individuals in the inner city of Los Angeles. Arch Gen Psychiatry, 1988. 45(12): p. 1085–92.
, , and ,
et al., HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. Jama, 1994. 272(6): p. 455–61.
Beck Depression Inventory (BDI-II) Manual. 1996, The Psychological Corporation: San Antonio, Texas, U.S.A. , and ,
et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids, 2000. 14(4): p. 357–66.
et al., Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology, 2001. 34(1): p. 180–7.
et al., Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol, 2002. 155(7): p. 645–53.
et al., Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol, 1998. 18(Suppl 1): p. S11–9.
et al., Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol, 1997. 35(12): p. 3274–7.
et al., Experience of an urban hospital referral clinic for evaluation of patients co-infected with HIV and hepatitis C virus (HCV). in 39th Annual Meeting of the Infectious Diseases Society of America. 2001, San Francisco, CA. ,
et al., Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol, 2002. 97(1): p. 149–55.
et al., Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. Jama, 1998. 280(24): p. 2088–93.
The epidemiology of hepatitis C. in NIH Consensus Development Conference: Management of Hepatitis C. 1997. Bethesda, MD. ,
et al., Viral hepatitis in the U.S. military: a study of hospitalization records from 1974 to 1999. Mil Med, 2001. 166(10): p. 862–5.
et al., Barriers to use of free antiretroviral therapy in injection drug users [see comments]. Jama, 1998. 280(6): p. 547–9.
et al., Self-reported antiretroviral therapy in injection drug users. Jama, 1998. 280(6): p. 544–6.
et al., Viral Hepatitis, Liver Damage, and Antiretroviral Prescribing Patterns in an HIV Community Network. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA. ,
et al., Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. Am J Public Health, 2002. 92(8): p. 1254–6.
Survey of local health department capacity for hepatitis C and HIV/AIDS prevention and control programs. in 128th Annual Meeting of the APHA. 2000. Boston, MA. and ,
Hepatitis C Infection: Epidemiology. 2000, San Francisco Department of Public Health: San Francisco, CA. ,
et al., Adherence to Guidelines among HIV/HCV Co-Infected Persons and Providers. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA. ,
et al., Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis, 2003. 36(8): p. 1039–46.
National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C, 2002. 2002.
National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 2S–10S.
Barriers to cadaveric renal transplantation among blacks, women, and the poor. JAMA, 1998. 280(13): p. 1148–52.
et al., The effect of race and sex on physicians’ recommendations for cardiac catheterization. New England Journal of Medicine, 1999. 340(8): p. 618–26.
et al., Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med, 2001. 345(3): p. 211–5.
et al., Treatment of hepatitis C infection in injection drug users. Hepatology, 2001. 34(1): p. 188–93.
Sustained virologic response in methadone patients treated for HCV. in 52nd Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases (AASLD). 2001. Dallas, TX. ,
et al., Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. Aids, 2001. 15(16): p. 2109–17.
et al., A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med, 2001. 134(10): p. 968–77.
et al., Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis, 2001. 33(8): p. 1417–23.
et al., Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000. 133(1): p. 21–30.
et al., Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis, 2001. 33(5): p. 700–5.
et al., Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr, 2001. 26(5): p. 435–42.
When should we delay highly active antiretroviral therapy? J Gen Intern Med, 1999. 14(7): p. 446–8.
et al., Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 2002. 35(2): p. 433–9.
et al., Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med, 1987. 147(9): p. 1577–80.
et al., Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics, 2001. 42(4): p. 365–7.
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology, 1999. 29(1): p. 264–70.
et al., Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 2002. 35(3): p. 704–8.
et al., Depression and use of mental health services among HIV-infected men. AIDS Care, 1996. 8(4): p. 433–42.
et al., Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med, 2000. 15(5): p. 311–20.
Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend, 2001. 61(3): p. 211–5.
, , and ,
et al., Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol, 2001. 96(9): p. 2730–6.
et al., Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol, 2000. 38(2): p. 575–7.
Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr, 2001. 26(4): p. 340–4.
, , and ,
et al., Protease inhibitors in the homeless. Jama, 1997. 278(1): p. 63–5.
Hepatitis C among drug users: deja vu all over again? Am J Public Health, 2001. 91(1): p. 21–2.
et al., Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health, 2000. 90(5): p. 699–701.